LONDON (Alliance News) - C4X Discovery Holdings PLC said Wednesday it appointed Eva-Lotta Allan as its new chair and Natalie Walter as non-executive director with immediate effect.
Allan is a former chief business officer at Immunocore "where she held full responsibility for all aspects of business development and played an instrumental role in the USD320 million fundraising in 2015."
She has also served in senior roles in other healthcare firms and served as a board member of the UK Bioindustry Association.
"I am delighted to join C4X Discovery's experienced leadership team and board of directors at such an exciting time for the company," Allan said. "Its combination of cutting edge drug discovery technologies and proven ability to strike high value deals, such as the very recent USD294 million with Indivior, positions C4X exceptionally well for the future."
In late March, C4X and Indivior PLC signed a license agreement in which Indivior received exclusive global rights to develop and commercialise C4X's oral orexin-1 receptor antagonist program. The deal is worth up to USD294 million over time.
Allan will replace Interim Chairman Sam Williams who will be stepping down to focus on his other business interests.
Corporate finance lawyer Walter joins with over two decades of healthcare sector equity capital advice experience. She currently acts as general counsel to Oxford BioMedica PLC.
"I am very pleased to welcome Eva-Lotta and Natalie to the board," C4X Chief Executive Officer Clive Dix said. "They are both highly experienced leaders in the life sciences sector with outstanding track records across business and strategy development, legal and finance, as well as capital market transactions. I look forward to working with Eva-Lotta, Natalie and the rest of the board to realise our aim of becoming the world's most productive drug discovery engine."
Shares in C4X were flat at 95.00 pence on Wednesday.
